<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00099164</url>
  </required_header>
  <id_info>
    <org_study_id>HD36801-STTARS</org_study_id>
    <secondary_id>HD21410</secondary_id>
    <secondary_id>HD27869</secondary_id>
    <secondary_id>HD27917</secondary_id>
    <secondary_id>HD27860</secondary_id>
    <secondary_id>HD27915</secondary_id>
    <secondary_id>HD34116</secondary_id>
    <secondary_id>HD34208</secondary_id>
    <secondary_id>HD34136</secondary_id>
    <secondary_id>HD40500</secondary_id>
    <secondary_id>HD40485</secondary_id>
    <secondary_id>HD40544</secondary_id>
    <secondary_id>HD40545</secondary_id>
    <secondary_id>HD40560</secondary_id>
    <secondary_id>HD40512</secondary_id>
    <secondary_id>HD36801</secondary_id>
    <nct_id>NCT00099164</nct_id>
  </id_info>
  <brief_title>Trial of Progesterone in Twins and Triplets to Prevent Preterm Birth (STTARS)</brief_title>
  <official_title>A Randomized Trial of 17 Alpha-Hydroxyprogesterone Caproate for Prevention of Preterm Birth in Multifetal Gestation (STTARS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The George Washington University Biostatistics Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The George Washington University Biostatistics Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women pregnant with twins or triplets are at high risk of preterm birth, yet no intervention
      or approach has served to reduce this risk. A recently completed trial by the NICHD sponsored
      Maternal Fetal Medicine Units (MFMU) Network has, for the first time, demonstrated a
      treatment that substantially reduces the rate of preterm birth in women at high risk for
      preterm delivery (i.e. progesterone therapy). Preterm birth was reduced by 35% among
      progesterone-treated women with a singleton pregnancy when compared with women receiving
      placebo. The current trial compares weekly treatment by injection of progesterone with
      placebo in women pregnant with twins or triplets.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women with multifetal gestation face numerous risks in excess of those faced by women with
      singleton gestation. Preterm birth is by far the most common and the most significant of
      these problems, yet no intervention or approach has served to reduce this risk. The
      prevalence of preterm birth has risen dramatically in recent years, in large part due to
      Assisted Reproductive Technologies. Consequently, the problem of preterm birth has assumed an
      even greater role in contributing to perinatal morbidity and mortality. The recently
      completed trial by the NICHD sponsored Maternal Fetal Medicine Units (MFMU) Network has, for
      the first time, demonstrated a treatment (i.e. progesterone therapy) that substantially
      reduces the rate of preterm birth in women at high risk for preterm delivery because of a
      prior spontaneous preterm birth . Preterm birth was reduced by 35% among progesterone-treated
      women when compared with women receiving placebo. Given this dramatic benefit and the
      extremely high risk of preterm birth in women with multifetal gestation, a trial to evaluate
      the benefit of progesterone in women with multifetal pregnancy is appropriate and timely.
      This protocol outlines a randomized, double-masked clinical trial comparing weekly treatment
      by injection of 17 alpha-hydroxyprogesterone caproate (17P) with placebo in women with twin
      or triplet gestation. In an ancillary study, the pharmacokinetics and pharmacodynamics of 17P
      in multifetal gestation will be studied.

      This trial aims to enroll six hundred women with twin gestation and one hundred twenty women
      with triplet gestation between 16 weeks 0 days to 20 weeks 6 days. At the initial screening
      evaluation, and after signing the informed consent form, the patient will receive an
      injection of the placebo (1 ml inert castor oil). She will be asked to return after three
      days for randomization. During this compliance test period, an ultrasound exam will be
      scheduled, if not previously done. When the patient returns and if she still meets the
      inclusion criteria, she will be randomized to one of two treatments:

        -  17 a-hydroxyprogesterone caproate: weekly 1 ml injections containing 250 mg of 17P

        -  Placebo: weekly injections of 1 ml placebo inert castor oil

      Treatment will be given through 34 weeks 6 days gestation or delivery. At the time of consent
      to the main study, the patient will also be asked to participate in an ancillary study. If
      she agrees, she will have 30 cc of blood drawn at 24-28 weeks and at 32-35 weeks gestation. A
      pelvic exam will be done at the same two times to collect vaginal specimens and to determine
      Bishop score.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delivery prior to 35 weeks 0 days gestation</measure>
    <time_frame>Delivery Date</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal randomization to delivery interval of first fetus</measure>
    <time_frame>Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pPROM - spontaneous rupture of the membranes at least one hour prior to the start of labor, regular contractions accompanied by cervical change</measure>
    <time_frame>Duration of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indicated preterm delivery</measure>
    <time_frame>Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spontaneous preterm delivery</measure>
    <time_frame>Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cesarean delivery</measure>
    <time_frame>Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational age at delivery</measure>
    <time_frame>Length of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placement of cervical cerclage</measure>
    <time_frame>During pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal hospital days</measure>
    <time_frame>Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal complications such as preeclampsia, gestational diabetes, placental abruption, chorioamnionitis.</measure>
    <time_frame>Duration of pregnancy, delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite neonatal outcome, comprised of fetal or infant death, RDS, IVH (grades 3 and 4), PVL, NEC (stage II and III), BPD/chronic lung disease, ROP (stage III or higher), early onset sepsis including meningitis</measure>
    <time_frame>Early life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal and neonatal death</measure>
    <time_frame>Delivery, Early life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stillbirth</measure>
    <time_frame>Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Twin-twin transfusion syndrome</measure>
    <time_frame>During pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth weight and degree of birth weight discordance</measure>
    <time_frame>Birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant days in hospital, *Respiratory distress syndrome (RDS)</measure>
    <time_frame>Early life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient tachypnea of the newborn (TTN)</measure>
    <time_frame>Early life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchopulmonary dysplasia (BPD)/chronic lung disease</measure>
    <time_frame>Early life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistent pulmonary hypertension of the newborn (PPHN)</measure>
    <time_frame>Early life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ventilator support</measure>
    <time_frame>Early life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of supplemental oxygen</measure>
    <time_frame>Early life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Periventricular leukomalacia (PVL)</measure>
    <time_frame>Early life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraventricular hemorrhage (IVH)</measure>
    <time_frame>Early life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necrotizing enterocolitis (NEC)</measure>
    <time_frame>Early life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal sepsis/meningitis/urinary tract infection/ pneumonia</measure>
    <time_frame>Early life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizures, as documented by the attending physician</measure>
    <time_frame>Early life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinopathy of prematurity (ROP)</measure>
    <time_frame>Early life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small for gestational age (&lt;10th percentile).</measure>
    <time_frame>Early life</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">795</enrollment>
  <condition>Preterm Birth</condition>
  <condition>Pregnancy</condition>
  <condition>Multifetal</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17 alpha-hydroxyprogesterone caproate (17P)</intervention_name>
    <description>Study coded medication is 250 mg of 17P as a 1 ml intramuscular injection (or 1 ml of placebo inert oil). Patients are seen weekly to administer the study drug through 34 weeks 6 days gestation or delivery, whichever occurs first.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Twin or triplet pregnancy. Quadruplets reduced to triplets may be included, but no
             other prior reductions.

          -  Gestational age between 16 weeks 0 days to 20 weeks 6 days based on clinical
             information and evaluation of the first ultrasound.

          -  Signed patient authorization and consent form.

        Exclusion Criteria:

          -  Prior elective fetal reduction in the current pregnancy, except in the case of a
             quadruplet gestation reduced to triplets.

          -  Planned fetal reduction or planned termination

          -  Monoamniotic gestation

          -  Twin-twin transfusion syndrome

          -  Fetal death or imminent fetal demise

          -  Major fetal anomaly (e.g., gastroschisis, spina bifida, serious karyotypic
             abnormalities). An ultrasound examination from 12 weeks 0 days to 20 weeks 6 days by
             project estimated date of confinement (EDC) must be performed to rule out fetal
             anomalies

          -  Discordance in fetal size, defined as a discrepancy of 3 or more weeks in gestational
             age by ultrasound between the largest and the smallest fetus. Diagnosis is based on
             measurements made at the ultrasound done between 12 weeks 0 days and 20 weeks 6 days
             gestation

          -  Progesterone treatment used or planned after 14 weeks gestation

          -  Heparin therapy at a dose â‰¥ 10,000 units per day of unfractionated heparin, or any low
             molecular weight heparin during the current pregnancy, or thromboembolic disease for
             which such heparin treatment is planned (because of contraindication to intra-muscular
             injections)

          -  Current or planned cervical cerclage

          -  Uterine anomaly (uterine didelphys, bicornate uterus)

          -  Contraindication to intra-muscular injections

          -  Maternal medical conditions, such as: known idiopathic thrombocytopenia purpura (ITP)
             or a known platelet count less than 100,000 per cubic millimeter (because of
             contraindication to intra-muscular injections), hypertension requiring medication,
             diabetes managed with insulin or oral hypoglycemic agents

          -  Inability to arrange a pre-randomization ultrasound between 12 weeks 0 days and 20
             weeks 6 days gestation

          -  Participation in another interventional study that influences gestational age at
             delivery or neonatal morbidity or mortality

          -  Prenatal follow-up or delivery planned elsewhere (unless the study visits can be made
             as scheduled and complete outcome information can be obtained)

          -  Participation in this trial in a previous pregnancy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uma Reddy, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth A Thom, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Washington University Biostatistics Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dwight Rouse, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steve N Caritis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pittsburgh - Magee Womens Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dexel University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Magee Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - Southwest</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bsc.gwu.edu/mfmu/</url>
    <description>The public website of the NICHD Maternal Fetal Medicine Units (MFMU) Network</description>
  </link>
  <reference>
    <citation>Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, Spong CY, Hauth JC, Miodovnik M, Varner MW, Leveno KJ, Caritis SN, Iams JD, Wapner RJ, Conway D, O'Sullivan MJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003 Jun 12;348(24):2379-85. Erratum in: N Engl J Med. 2003 Sep 25;349(13):1299.</citation>
    <PMID>12802023</PMID>
  </reference>
  <reference>
    <citation>Kogan MD, Alexander GR, Kotelchuck M, MacDorman MF, Buekens P, Papiernik E. A comparison of risk factors for twin preterm birth in the United States between 1981-82 and 1996-97. Matern Child Health J. 2002 Mar;6(1):29-35.</citation>
    <PMID>11926251</PMID>
  </reference>
  <reference>
    <citation>Gardner MO, Goldenberg RL, Cliver SP, Tucker JM, Nelson KG, Copper RL. The origin and outcome of preterm twin pregnancies. Obstet Gynecol. 1995 Apr;85(4):553-7.</citation>
    <PMID>7898832</PMID>
  </reference>
  <reference>
    <citation>Min SJ, Luke B, Gillespie B, Min L, Newman RB, Mauldin JG, Witter FR, Salman FA, O'sullivan MJ. Birth weight references for twins. Am J Obstet Gynecol. 2000 May;182(5):1250-7.</citation>
    <PMID>10819867</PMID>
  </reference>
  <reference>
    <citation>Lynch A, McDuffie R, Stephens J, Murphy J, Faber K, Orleans M. The contribution of assisted conception, chorionicity and other risk factors to very low birthweight in a twin cohort. BJOG. 2003 Apr;110(4):405-10.</citation>
    <PMID>12699803</PMID>
  </reference>
  <reference>
    <citation>Goldenberg RL, Iams JD, Miodovnik M, Van Dorsten JP, Thurnau G, Bottoms S, Mercer BM, Meis PJ, Moawad AH, Das A, Caritis SN, McNellis D. The preterm prediction study: risk factors in twin gestations. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol. 1996 Oct;175(4 Pt 1):1047-53.</citation>
    <PMID>8885774</PMID>
  </reference>
  <results_reference>
    <citation>Caritis SN, Rouse DJ, Peaceman AM, Sciscione A, Momirova V, Spong CY, Iams JD, Wapner RJ, Varner M, Carpenter M, Lo J, Thorp J, Mercer BM, Sorokin Y, Harper M, Ramin S, Anderson G; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Maternal-Fetal Medicine Units Network (MFMU). Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Obstet Gynecol. 2009 Feb;113(2 Pt 1):285-92. doi: 10.1097/AOG.0b013e318193c677.</citation>
    <PMID>19155896</PMID>
  </results_reference>
  <results_reference>
    <citation>Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, Varner M, Malone F, Iams JD, Mercer BM, Thorp J, Sorokin Y, Carpenter M, Lo J, Ramin S, Harper M, Anderson G; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med. 2007 Aug 2;357(5):454-61.</citation>
    <PMID>17671253</PMID>
  </results_reference>
  <results_reference>
    <citation>Gyamfi C, Horton AL, Momirova V, Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Meis PJ, Spong CY, Dombrowski M, Sibai B, Varner MW, Iams JD, Mercer BM, Carpenter MW, Lo J, Ramin SM, O'Sullivan MJ, Miodovnik M, Conway D; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. Am J Obstet Gynecol. 2009 Oct;201(4):392.e1-5. doi: 10.1016/j.ajog.2009.06.036. Epub 2009 Aug 29.</citation>
    <PMID>19716543</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2004</study_first_submitted>
  <study_first_submitted_qc>December 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2004</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>preterm birth</keyword>
  <keyword>pregnancy</keyword>
  <keyword>multifetal</keyword>
  <keyword>Progesterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>17-alpha-hydroxy-progesterone caproate</mesh_term>
    <mesh_term>11-hydroxyprogesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data will be shared after completion and publication of the main analyses in accordance with NIH policy. The dataset can be obtained by emailing mfmudatasets@bsc.gwu.edu.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

